Throne Biotechnologies (Throne) is developing Stem Cell Educator therapy to treat type 1 diabetes (T1D) and other autoimmune/inflammation-associated diseases. T1D is an autoimmune disease that causes a deficit of islet beta cells. Millions of individuals worldwide have T1D, and incidence increases markedly since COVID-19 pandemic started. T1D patients are at increased risk for severe COVID-19. Recent clinical trials have highlighted the limits of conventional immune therapy and underscore the need for novel approaches that not only overcome multiple immune dysfunctions, but also help restore islet beta-cell function. To address these two key issues, Throne has developed a unique and novel Educator therapy by using a new type of cord blood-derived multipotent stem cells (CB-SC). With this patented technology, a patient’s blood is circulated through a blood cell separator, where the patient’s immune cells are co-cultured with adherent CB-SC in vitro, and returns “educated” immune cells to the patient’s circulation. Over the last 10 years, our technology has been evaluated through international multi-center clinical studies, where we have demonstrated the clinical efficacy and safety of Educator Therapy. Notably, Educator therapy is the only therapy to date to safely and efficiently correct autoimmunity and restore beta-cell function in T1D patients. Our Stem Cell Educator technology is recognized and retained as the leading “Practical Cure Project” for type 1 diabetes out of 590 global projects (Juvenile Diabetes Cure Alliance (JDCA) 2021, New York). See the JDCA’s tenth annual edition of the State of the Cure.